This content is in French.
Acute myeloid leukemia: targeting the CD81 protein to prevent relapse
28 avril 2026
By Elodie Vaz | Published on April 28, 2026 | 3 min readAcute myeloid leukemia (AML) is the most common form of acute leukemia in adults, with incidence increasing after the age of 60. This hematologic malignancy is characterized by uncontrolled proliferation of immature cells—blasts—in the bone marrow and peripheral blood, disrupting normal hematopoiesis. Despite recent therapeutic advances, prog
By Elodie Vaz | Published on April 28,
2026 | 3 min read
Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults, with incidence increasing after the age of 60. This hematologic malignancy is characterized by uncontrolled proliferation of immature cells—blasts—in the bone marrow and peripheral blood, disrupting normal hematopoiesis. Despite recent therapeutic advances, prognosis remains poor, largely due to a high rate of relapse. These treatment failures are mainly attributed to a rare subpopulation of leukemic stem cells (LSCs), which can evade conventional cytotoxic therapies and reinitiate the disease.
In this context, a team from the Lille Interdisciplinary Cancer Research Center (Inserm/University of Lille/Lille University Hospital/CNRS) investigated the membrane protein CD81. Already known to be involved in interprotein communication within the cell membrane and overexpressed in certain cancers, this protein may play a key role in LSC biology. The aim of the study was to evaluate its relevance as both a prognostic biomarker and a therapeutic target in AML.
Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults, with incidence increasing after the age of 60. This hematologic malignancy is characterized by uncontrolled proliferation of immature cells—blasts—in the bone marrow and peripheral blood, disrupting normal hematopoiesis. Despite recent therapeutic advances, prognosis remains poor, largely due to a high rate of relapse. These treatment failures are mainly attributed to a rare subpopulation of leukemic stem cells (LSCs), which can evade conventional cytotoxic therapies and reinitiate the disease.
In this context, a team from the Lille Interdisciplinary Cancer Research Center (Inserm/University of Lille/Lille University Hospital/CNRS) investigated the membrane protein CD81. Already known to be involved in interprotein communication within the cell membrane and overexpressed in certain cancers, this protein may play a key role in LSC biology. The aim of the study was to evaluate its relevance as both a prognostic biomarker and a therapeutic target in AML.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Surface CD81 soutient la fonction des cellules souches leucémique et révèle une vulnérabilité thérapeutique dans la leucémie myéloïde aiguë
View the source
